News

Date:
VANCOUVER, BC, Canada – biOasis Technologies Inc. (OTCQB: BIOAF; TSX.V: BTI), a biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB) and into the central nervous system for the treatment of neurological diseases and…
Date:
PRNewswire: September 6, 2017 – LEXINGTON, MA, U.S.A. – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has partnered with Vectura Group plc (LSE: VEC) (“Vectura”) to…
Date:
Business Wire: September 5, 2017 – BALERNA, Switzerland – APR Applied Pharma Research s.a. (“APR”), the Swiss independent developer of science driven and patent protected healthcare products, announced today the results of a preclinical kinetic study showing a physiological absorption of clinically…
Date:
Business Wire: August 29, 2017 – BOSTON, MA, U.S.A. – PureTech Health plc (“PureTech Health” or the “company”, LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, today announced an exclusive licensing agreement with Monash University for a lymphatic targeting platform (the Glyph…
Date:
PRNewswire: August 29, 2017 – SAN DIEGO, CA, U.S.A. – Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”), announced today that Scilex Pharmaceuticals Inc. (“Scilex”), a majority-owned subsidiary of Sorrento, resubmitted the NDA and responded to all of FDA comments related to the initial NDA…
Date:
PRNewswire: August 24, 2017 – SOUTH SAN FRANCISCO, CA, U.S.A. – Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its ropinirole implant intended for treatment of the signs and…